Functional biomarkers are objective measurements that reflect the process and progression of a disease, and the effect of drug intervention. They enable everything from earlier, more accurate disease ...

While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...

KineMed, Inc. has announced a further award of $1.2 Million from The Michael J. Fox Foundation towards the ongoing development of kinetic biomarkers that drug developers can use to accelerate and ...

The Prognostic Lung Fibrosis Consortium (PROLIFIC), a collaborative consortium advancing biomarker tools for pulmonary ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...

The FDA and the EMEA are testing a Pilot Process for Biomarker Qualification, which was created based on the specific need for new biomarkers in drug development. This Pilot Process needs to be tested ...

SAN DIEGO & TOKYO & MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective ...